Group 1 - The core point of the article highlights the stock performance of Yinos, which increased by 5.19% to reach a price of 58.18 CNY per share, with a trading volume of 181 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 8.202 billion CNY [1] - Yinos is a biotechnology company based in the China (Shanghai) Free Trade Zone, established on May 12, 2010, and listed on September 3, 2024. The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Among the top ten circulating shareholders of Yinos, a fund under Huatai-PineBridge is noted, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top ten shareholders in the third quarter with 1.1215 million shares, accounting for 1.24% of circulating shares. The estimated floating profit for today is approximately 3.2188 million CNY [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY. Year-to-date returns are 6.72%, ranking 749 out of 8825 in its category, while the one-year return is 36.03%, ranking 3440 out of 8084. Since its inception, the fund has achieved a return of 162.46% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a cumulative tenure of 11 years and 26 days. The total asset scale under his management is 8.093 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -35.19% [2]
益诺思股价涨5.19%，汇添富基金旗下1只基金位居十大流通股东，持有112.15万股浮盈赚取321.88万元